Comparative Pharmacology
Head-to-head clinical analysis: SARISOL versus SARISOL NO 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SARISOL versus SARISOL NO 2.
SARISOL vs SARISOL NO. 2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP levels, leading to bronchodilation.
SARISOL NO. 2 contains butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing pain and fever. Caffeine is a CNS stimulant that antagonizes adenosine receptors.
500 mg orally twice daily or 250 mg orally three times daily.
Butalbital 50 mg, acetaminophen 325 mg, and caffeine 40 mg per tablet; 1 to 2 tablets orally every 4 hours as needed, not to exceed 6 tablets per day.
None Documented
None Documented
12-15 hours; prolonged to 24-30 hours in severe hepatic impairment.
Terminal elimination half-life is 12-15 hours; prolonged in hepatic impairment.
Renal (65% unchanged, 20% as metabolites), biliary/fecal (15%).
Renal excretion of unchanged drug and metabolites; 70% renal, 30% biliary/fecal.
Category C
Category C
Topical Anti-acne Agent
Topical Anti-acne Agent